Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
3,000
Oral Tablet
Hallym University Dongtan Sacred Heart Hospital /ID# 273581
Hwaseong, Gyeonggido, South Korea
RECRUITINGSeoul National University Hospital /ID# 271892
Seoul, Seoul Teugbyeolsi, South Korea
RECRUITINGKangbuk Samsung Hospital /ID# 271893
Seoul, Seoul Teugbyeolsi, South Korea
RECRUITINGYonsei University Health System Severance Hospital /ID# 272639
Seoul, Seoul Teugbyeolsi, South Korea
RECRUITINGPercentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)
Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)
Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported known (labeled) ADR
Percentage (%) of participants who reported known (labeled) ADR
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported non-serious AE/ADR
Percentage (%) of participants who reported non-serious AE/ADR
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the Risk Management Plan (RMP)
Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the RMP
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with AE: overall summary
Percentage (%) of participants with AE: overall summary
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with common (>=5%) AE
Percentage (%) of participants with common (\>=5%) AE
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants with AE leading to treatment discontinuation
Percentage (%) of participants with AE leading to treatment discontinuation
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment
Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment
Time frame: Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment
Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment
Time frame: Up to approximately 16 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.